Global Womens Healthcare Market is Projected to Reach USD 17.8 Billion By 2024 From USD 9.6 Billion in 2019 with a CAGR of 13.2% - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Feb 4, 2020--
The “Women’s Health Care Market by Drugs (Prolia, Xgeva, Evista, Mirena, Zometa, Reclast, Nuvaring, Primarin, Actonel), Application (Female Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraception, PCOS, Menopause) - Global forecast to 2024” report has been added to ResearchAndMarkets.com’s offering.
The global women’s healthcare market is projected to reach USD 17.8 billion by 2024 from USD 9.6 billion in 2019, at a CAGR of 13.2% during the forecast period.
Growing incidence of chronic health conditions among women and the demand in contraceptives to prevent unintended pregnancies are the key factors driving the women’s healthcare market.
Growth in this market is mainly driven by the growing incidence of chronic health conditions among women, growing demand for contraceptives to prevent unintended pregnancies, growing focus on R&D by key players for the development of advanced products, and the government initiatives to curb population growth. On the other hand, the reluctance to use contraceptives is a major factor limiting the market growth.
Prolia is the largest and fastest-growing segment of the market.
On the basis of drug, the women’s healthcare market is segmented into EVISTA, XGEVA, Prolia, Mirena, Zometa, Reclast/Aclasta, Minastrin 24 Fe, NuvaRing, FORTEO, Premarin, ACTONEL, and ORTHO-TRI-CY LO (28). Prolia is the largest and fastest-growing segment of the market. The increasing unit demand for Prolia due to the high prevalence of postmenopausal osteoporosis among women in the US is one of the major factors responsible for the large share and high growth rate of this drug.
The postmenopausal osteoporosis segment accounted for the largest share in 2019.
Based on application, the women’s healthcare market is segmented into hormonal infertility, postmenopausal osteoporosis, endometriosis, contraceptives, menopause, PCOS, and other applications. The postmenopausal osteoporosis segment accounted for the largest share of the women’s healthcare market in 2018. The growing prevalence of postmenopausal osteoporosis and the focus of pharmaceutical players on providing effective drugs for the treatment of postmenopausal osteoporosis are some of the key factors supporting the growth of this segment. This segment is also expected to register the highest CAGR during the forecast period.
North America to be the largest and the fastest-growing regional market.
North America, which comprises the US and Canada, forms the largest market for women’s healthcare. Growing awareness and understanding regarding contraceptives among American women, easy access to modern contraception as compared to developing countries, and increased healthcare spending are some of the major factors responsible for the large share and high growth of this market. Additionally, the increasing median age of first-time pregnancies and the growing prevalence of PCOS & postmenopausal osteoporosis also propels the market growth in this region.
Key Benefits of Buying the Report:
Key Topics Covered:
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Markets Covered
1.3.2 Years Considered for the Study
2 Research Methodology
2.1 Research Data
2.1.1 Secondary Sources
22.214.171.124 Key Data From Secondary Sources
2.1.2 Primary Sources
126.96.36.199 Key Data From Primary Sources
188.8.131.52 Key Industry Insights
2.2 Market Size Estimations
2.3 Market Breakdown and Data Triangulation
2.4 Assumptions for the Study
3 Executive Summary
4 Premium Insights
4.1 Women’s Healthcare Market Overview
4.2 Market, By Drug (2019-2024)
4.3 Market, By Application (2019 vs 2024)
4.4 Market: Geographic Growth Opportunities
5 Market Overview
5.2 Market Dynamics
5.10 Ortho Tri-Cy Lo (28)
5.14 Minastrin 24 FE
5.16 Pipeline Drugs
6 Women’s Healthcare Market, By Application
6.2 Postmenopausal Osteoporosis
6.5 Hormonal Infertility
6.6 Polycystic Ovary Syndrome
6.8 Other Applications
7 Women’s Healthcare Market, By Region
7.2 North America
7.4 Asia Pacific
7.5 Latin America
7.6 Middle East & Africa
8 Competitive Landscape
8.2 Market Share Analysis
8.3 Competitive Leadership Mapping
9 Company Profiles
9.1 Bayer AG
9.3 Merck & Co
9.6 Agile Therapeutics
9.7 Ferring Pharmaceuticals
9.8 Mylan NV
9.9 Lupin Limited
9.10 Blairex Laboratories, Inc.
9.11 Apothecus Pharmaceutical Corporation
9.12 Eli Lilly and Company
9.13 Novartis AG
9.14 Johnson & Johnson Services Inc.
For more information about this report visit https://www.researchandmarkets.com/r/cbhctu
View source version on businesswire.com:https://www.businesswire.com/news/home/20200204005558/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: MEDICAL DEVICES WOMEN CONSUMER HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2020.
PUB: 02/04/2020 07:20 AM/DISC: 02/04/2020 07:21 AM